Optipharm.CO.,LTD (KOSDAQ:153710)

Kronos Bio Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,474	3,622	2,254	5,573	8,187	15,725
Short-Term Investments	9,641	10,610	13,396	11,048	13,919	6,444
Cash & Short-Term Investments	11,115	14,231	15,651	16,621	22,106	22,169
Cash Growth	-29.63%	-9.07%	-5.84%	-24.81%	-0.28%	-13.11%
Accounts Receivable	1,185	1,089	1,369	1,124	1,001	863.24
Other Receivables	2,266	274.01	268.86	972.95	173.3	172.83
Receivables	3,535	1,498	1,783	2,231	1,314	1,235
Inventory	1,794	1,313	1,320	1,099	1,056	716.88
Prepaid Expenses	146.83	303.42	327.28	316.77	497.53	981.89
Other Current Assets	1,599	1,329	1,395	1,279	893.95	573.7
Total Current Assets	18,189	18,675	20,476	21,548	25,867	25,676
Property, Plant & Equipment	24,915	23,789	18,325	17,717	13,613	13,347
Long-Term Investments	0	0	0	985.74	986.09	986.39
Other Intangible Assets	293.6	295.01	281.51	258.4	263.82	272.36
Other Long-Term Assets	539.34	559.74	193.34	673.72	438.74	1,040
Total Assets	43,937	43,319	39,275	41,182	41,168	41,321
Accounts Payable	488.63	405.39	581.26	503.35	575.04	383.31
Accrued Expenses	294.89	445.72	437.63	101.92	76.1	68.29
Short-Term Debt	10,660	10,750	9,610	7,470	5,830	4,290
Current Portion of Leases	124.46	124.85	148.32	90.25	102.31	10.88
Current Unearned Revenue	2,070	47.43	-	-	-	-
Other Current Liabilities	647.8	960.28	823.69	1,098	1,267	771.7
Total Current Liabilities	14,285	12,734	11,601	9,264	7,851	5,524
Long-Term Leases	136.31	133.84	287.95	164.08	47.15	179.84
Long-Term Unearned Revenue	804.86	853.11	887.03	1,146	324.51	225.72
Long-Term Deferred Tax Liabilities	1,094	1,094	-	-	-	-
Other Long-Term Liabilities	47.58	45.8	41.08	38.74	37.91	31.38
Total Liabilities	17,564	15,983	14,131	12,171	10,213	7,541
Common Stock	7,335	7,335	7,335	7,335	7,295	7,237
Additional Paid-In Capital	44,031	44,031	41,982	41,982	41,710	41,211
Retained Earnings	-28,974	-27,835	-25,299	-22,404	-20,243	-16,990
Comprehensive Income & Other	3,981	3,805	1,127	2,098	2,193	2,321
Shareholders' Equity	26,373	27,335	25,144	29,011	30,955	33,780
Total Liabilities & Equity	43,937	43,319	39,275	41,182	41,168	41,321
Total Debt	10,921	11,009	10,046	7,724	5,979	4,481
Net Cash (Debt)	193.8	3,223	5,605	8,897	16,126	17,688
Net Cash Growth	-95.57%	-42.50%	-37.00%	-44.83%	-8.83%	-19.43%
Net Cash Per Share	13.19	219.68	381.82	609.19	1110.10	1225.67
Filing Date Shares Outstanding	14.67	14.67	14.67	14.67	14.59	14.47
Total Common Shares Outstanding	14.67	14.67	14.67	14.67	14.59	14.47
Working Capital	3,904	5,941	8,875	12,284	18,016	20,151
Book Value Per Share	1797.77	1863.36	1714.00	1977.60	2121.75	2333.75
Tangible Book Value	26,080	27,040	24,863	28,753	30,691	33,507
Tangible Book Value Per Share	1777.76	1843.25	1694.81	1959.99	2103.67	2314.93
Land	8,816	8,816	3,583	3,583	3,583	3,583
Buildings	10,315	14,380	14,380	10,936	10,403	10,392
Machinery	2,849	9,115	8,220	6,909	5,776	5,224
Construction In Progress	2,286	809.03	-	3,128	573.74	12.4

Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.